Nykode Therapeutics AS (VACBF) Q4 2025 Earnings Call Highlights: Navigating Financial ... [Yahoo! Finance]
ROCHE HOLDING LTD S/ADR (RHHBY)
NASDAQ:AMEX Investor Relations:
roche.com/investors.htm
Company Research
Source: Yahoo! Finance
This article first appeared on GuruFocus Revenue: No revenue in Q4 2025 compared to $6.8 million in Q4 2024. Operating Expenses: Reduced from $12.9 million in Q4 2024 to $8.1 million in Q4 2025. Net Loss: $8 million in Q4 2025 compared to $6.8 million in Q4 2024. Cash Position: $60.3 million at the end of 2025. Equity: Total equity of $91.5 million with an equity ratio of 92%. Objective Response Rate: 38.5% in VB-C-03 trial for first line head and neck cancer. Cash Runway: Estimated to last into 2028, potentially extending to 2029 with a positive tax case outcome. Warning! GuruFocus has detected 6 Warning Signs with VACBF. Is VACBF fairly valued? Test your thesis with our free DCF calculator. Release Date: February 25, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript Positive Points Nykode Therapeutics AS ( VACBF ) is well-capitalized with a cash runway extending into 2028, providing financial stability
Show less
Read more
Impact Snapshot
Event Time:
RHHBY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RHHBY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RHHBY alerts
High impacting ROCHE HOLDING LTD S/ADR news events
Weekly update
A roundup of the hottest topics
RHHBY
News
- Roche Holding (SWX:ROG) Valuation Check After Key FDA And Phase III Milestones [Yahoo! Finance]Yahoo! Finance
- Parker Institute for Cancer Immunotherapy Announces Appointment of Bob Purcell as Chief Communications Officer [Yahoo! Finance]Yahoo! Finance
- BreezeBio banks $60M to make more precise genetic medicines [Yahoo! Finance]Yahoo! Finance
- Flatiron Health Attends the 2026 American Society of Genitourinary Cancers Symposium to Answer Oncology's Most Critical QuestionsBusiness Wire
- FDA Approves Genentech’s Venclexta® Plus Acalabrutinib Combination Regimen for Previously Untreated Chronic Lymphocytic LeukemiaBusiness Wire